Generate a tailored SOP for Dr. Michael Von Bergwelt Baildon. Improve your application with a focused, well-structured draft.
Michael von Bergwelt-Baildon is a distinguished researcher specializing in B-cell-targeted immunotherapies and combination therapies, particularly focusing on CAR-T-cell treatments. He coordinates research efforts in the field of translational immunology and contributes significantly to the understanding of antigen presentation by B-cells and the identification of functional B-cell subpopulations. His academic contributions have also delved into the metabolic processes that underpin immune responses in oncology. He is committed to advancing clinical studies that investigate the efficacy and safety of immunotherapies for various malignancies, including lymphoma and leukemia. In collaboration with national and international research partnerships, he strives to translate basic research findings into clinical applications aimed at improving patient outcomes in the treatment of cancers. His notable publications include insights into the mechanisms of immune responses to B-cell malignancies and the role of metabolic changes in immune cell functionality.
Ludwig Maximilian University of Munich • Munich, Germany
Leading a research group focused on B-cell-based immunotherapy and translational research in cancer treatment.
Administered by the Faculty of Economics. GRE is NOT required for the standard M.Sc. Economics.